87 related articles for article (PubMed ID: 10209523)
21. Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis.
Shahane A
Rheumatol Int; 2013 Jul; 33(7):1655-67. PubMed ID: 23334373
[TBL] [Abstract][Full Text] [Related]
22. Immune and inflammatory mechanisms in pulmonary arterial hypertension.
El Chami H; Hassoun PM
Prog Cardiovasc Dis; 2012; 55(2):218-28. PubMed ID: 23009917
[TBL] [Abstract][Full Text] [Related]
23. Levosimendan attenuates pulmonary vascular remodeling.
Revermann M; Schloss M; Mieth A; Babelova A; Schröder K; Neofitidou S; Buerkl J; Kirschning T; Schermuly RT; Hofstetter C; Brandes RP
Intensive Care Med; 2011 Aug; 37(8):1368-77. PubMed ID: 21626431
[TBL] [Abstract][Full Text] [Related]
24. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension.
Filusch A; Zelniker T; Baumgärtner C; Eschricht S; Frey N; Katus HA; Chorianopoulos E
Clin Res Cardiol; 2011 Oct; 100(10):879-85. PubMed ID: 21479966
[TBL] [Abstract][Full Text] [Related]
25. Lactoferrin inhibits the inflammatory and angiogenic activation of bovine aortic endothelial cells.
Yeom M; Park J; Lee B; Choi SY; Kim KS; Lee H; Hahm DH
Inflamm Res; 2011 May; 60(5):475-82. PubMed ID: 21161563
[TBL] [Abstract][Full Text] [Related]
26. Mixed connective tissue disease presenting as a peculiar myositis with poor muscle regeneration.
Tasca G; Mirabella M; Berrettini A; Monforte M; Tonali PA; Ricci E
Neurol Sci; 2011 Feb; 32(1):171-4. PubMed ID: 20890626
[TBL] [Abstract][Full Text] [Related]
27. Systemic sclerosis-associated pulmonary arterial hypertension.
Le Pavec J; Humbert M; Mouthon L; Hassoun PM
Am J Respir Crit Care Med; 2010 Jun; 181(12):1285-93. PubMed ID: 20194816
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension.
Crosswhite P; Sun Z
J Hypertens; 2010 Feb; 28(2):201-12. PubMed ID: 20051913
[TBL] [Abstract][Full Text] [Related]
29. Vasculitis: mechanisms involved and clinical manifestations.
Guillevin L; Dörner T
Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S9. PubMed ID: 17767747
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease.
Zhang L; Visscher D; Rihal C; Aubry MC
Rheumatol Int; 2007 Oct; 27(12):1163-5. PubMed ID: 17520258
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary hypertension in a patient with adult-onset Stills disease.
Mubashir E; Ahmed MM; Hayat S; Heldmann M; Berney SM
Clin Rheumatol; 2007 Aug; 26(8):1359-61. PubMed ID: 16871352
[TBL] [Abstract][Full Text] [Related]
32. [Cardiovascular monitoring of patients with systemic lupus erythematosus].
Schotte H; Becker H; Domschke W; Gaubitz M
Z Rheumatol; 2005 Nov; 64(8):564-75. PubMed ID: 16328762
[TBL] [Abstract][Full Text] [Related]
33. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension.
Tamby MC; Chanseaud Y; Humbert M; Fermanian J; Guilpain P; Garcia-de-la-Peña-Lefebvre P; Brunet S; Servettaz A; Weill B; Simonneau G; Guillevin L; Boissier MC; Mouthon L
Thorax; 2005 Sep; 60(9):765-72. PubMed ID: 16135682
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein.
Okawa-Takatsuji M; Aotsuka S; Fujinami M; Uwatoko S; Kinoshita M; Sumiya M
Clin Exp Immunol; 1999 Apr; 116(1):174-80. PubMed ID: 10209523
[TBL] [Abstract][Full Text] [Related]
35. Increase of cytokine production by pulmonary artery endothelial cells induced by supernatants from monocytes stimulated with autoantibodies against U1-ribonucleoprotein.
Okawa-Takatsuji M; Aotsuka S; Uwatoko S; Kinoshita M; Sumiya M
Clin Exp Rheumatol; 1999; 17(6):705-12. PubMed ID: 10609069
[TBL] [Abstract][Full Text] [Related]
36. Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases.
Okawa-Takatsuji M; Aotsuka S; Uwatoko S; Takaono M; Iwasaki K; Kinoshita M; Sumiya M
Clin Exp Immunol; 2001 Nov; 126(2):345-54. PubMed ID: 11703381
[TBL] [Abstract][Full Text] [Related]
37. Enhanced synthesis of cytokines by peripheral blood monocytes cultured in the presence of autoantibodies against U1-ribonucleoprotein and/or negatively charged molecules: implication in the pathogenesis of pulmonary hypertension in mixed connective tissue disease (MCTD).
Okawa-Takatsuji M; Aotsuka S; Uwatoko S; Sumiya M; Yokohari R
Clin Exp Immunol; 1994 Dec; 98(3):427-33. PubMed ID: 7994907
[TBL] [Abstract][Full Text] [Related]
38. Autoantibodies in the pathogenesis of mixed connective tissue disease.
Greidinger EL; Hoffman RW
Rheum Dis Clin North Am; 2005 Aug; 31(3):437-50, vi. PubMed ID: 16084317
[TBL] [Abstract][Full Text] [Related]
39. Anti-RNP immunity: implications for tissue injury and the pathogenesis of connective tissue disease.
Keith MP; Moratz C; Tsokos GC
Autoimmun Rev; 2007 Mar; 6(4):232-6. PubMed ID: 17317614
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
